Table 1.
Demographic characteristics of 51 consecutive patients and 33 controls
| Cases (n = 51) | Controls (n = 33) | |
|---|---|---|
| Age, years | 61 (52; 69) | 47 (39; 61) |
| Sex, females | 49/51 (96) | 19/33 (58) |
| Current/not current smokers | 4/51 (8) | 7/33 (21) |
| Ever/never smokers | 24/51 (47) | NA |
| Fulfilling the AECG for pSS | 51/51 (100) | NA |
| Fulfilling the ACR/EULAR criteria for pSS | 51/51 (100) | NA |
| Disease duration, years | 12 (6; 18) | NA |
| Anti-SSA antibody seropositives | 40/51 (78) | NA |
| Anti-SSB antibody seropositives | 24/51 (47) | NA |
| ANA seropositives | 40/51 (78) | NA |
| RF seropositives | 26/51 (51) | NA |
| IgG, g/l | 13.0 (10.1; 15.5) | NA |
| C3, g/l | 1.01 (0.86; 1.20) | NA |
| C4, g/l | 0.18 (0.13; 0.21) | NA |
| Lower lip biopsy, focus score ≥ 1% | 37/40 (93) | NA |
| ESSPRI total score | 6 (5; 7) | NA |
| ESSDAI total score | 7 (1; 10) | NA |
| Nonexocrine symptoms/signs, any of the below % | 25/51 (49) | NA |
| Lymphadenopathy and/or lymphoma ever % | 3/51 (6) | NA |
| Arthritis ever % | 4/51 (8) | NA |
| Cutaneous symptoms ever % | 10/51 (20) | NA |
| Interstitial lung disease evera % | 9/51 (18) | NA |
| Chronic obstructive lung disease ever % | 21/51 (41) | NA |
| Renal involvement ever % | 4/51 (8) | NA |
| Myositis ever % | 0/51 (0) | NA |
| Peripheral nervous system involvement ever % | 1/51 (2) | NA |
| Raynaud phenomenon ever % | 4/51 (8) | NA |
Disease characteristics of the 51 consecutive patients with pSS. Values are presented as n/n available (%) or median (IQR) unless otherwise specified
pSS primary Sjögren’s syndrome, AECG American-European Consensus Group criteria, ACR American College of Rheumatology, EULAR European League Against Rheumatism, ANA antinuclear antibody, RF rheumatoid factor, IgG immunoglobulin G, C3 complement factor 3, C4 complement factor 4, ESSPRI EULAR Sjögren Patient Reported Index, ESSDAI EULAR Sjögren Disease Activity Index, EULAR European League Against Rheumatism, ILD interstitial lung disease
aDefined as presence of peripheral traction bronchiectasis, honey combing or ground glass opacities